Evolving Treatment Landscape in Myelodysplastic Syndromes

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.

Hematologist-oncologists address adverse event management and discuss the unmet needs of patients with lower-risk MDS and symptomatic anemia.

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

The expert panel discusses abstracts surrounding the IMerge clinical trial on imetelstat in patients with lower-risk myelodysplastic syndromes.

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

The panel discusses emerging clinical trials in the MDS treatment space and offers key takeaways from the 2023 ASH Annual Meeting.

Comprehensive insights on the current treatment landscape and remaining unmet needs for patients with higher-risk MDS.

Hematologist-oncologists review clinical trial data updates presented at ASH 2023 in higher-risk MDS.

Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.